Ophthalmology Deal Benchmarks
AMD, glaucoma, dry eye, and retinal disease deal benchmarks. Benchmarks derived from 64 verified transactions.
64
Total Deals
$757M
Avg Upfront
6
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
22
license
20
acquisition
9
collaboration
9
option
2
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Apellis Pharmaceuticals → Biogen Empaveli / Syfovre | acquisition | $5.6B | $5.6B | Jun 2026 |
MeiraGTx → Johnson & Johnson Bota-vec | acquisition | $130M | $130M | Apr 2026 |
MeiraGTx → Eli Lilly AAV-AIPL1 | license | $75M | — | Mar 2026 |
Ocugen → Kwangdong Pharmaceutical OCU400 | license | $8M | $180M | Sep 2025 |
Adverum Biotechnologies → Eli Lilly Ixoberogene soroparvovec (ixo-vec) acquisition | acquisition | $261M | $261M | Dec 2024 |
EyeBio → Merck retinal_disease | acquisition | $1.3B | $3.0B | Nov 2024 |
Surrozen → Boehringer Ingelheim SZN-413 (Wnt modulator for retina) | co development | $40M | $599M | Jun 2024 |
MeiraGTx → Eli Lilly AAV gene therapy (ophtho collaboration) | co development | $50M | $475M | Jun 2024 |
Ocugen → Bharat Biotech OCU400 | license | $8M | $200M | Feb 2024 |
Aldeyra Therapeutics → AbbVie Reproxalap (dry eye) | option | $100M | $400M | Jan 2024 |
Benchmark Your Ophthalmology Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 64 verified ophthalmology transactions.
Run Ophthalmology Benchmark